Welcome! You are invited to join a webinar: [Live Webinar] – Optimising the management of HR+ HER2- metastatic breast cancer. After registering, you will receive a confirmation email about joining the webinar.

Join this webinar on Wednesday 22 January 2025, 19:00-20:00 CET, where Etienne Brain, Evandro de Azambuja, Valentina Guarneri, Cristina Saura and Hans Wildiers will discuss the management of hormone receptor-positive, HER2-negative metastatic breast cancer. EACCME accreditation for attending the live webinar has been applied for.

Read the full article here

Source: us02web.zoom.us

Categories: Oncologists1, General Medicine News

Tags: BreastCancer

Tweets with this article

OncoAlert

Join our collaborators at @MirrorsMed for a webinar on Wednesday, 22 January 2025, from 19:00 to 20:00 CET Optimising the management of HR+ HER2- met #BreastCancer SIGN UP HERE https://t.co/WpqVGhyvhl as experts @EtienneB66 @E_de_Azambuja Valentina Guarneri,… https://t.co/aqJPO0biHr https://t.co/cZGLdYrqMW

Vagus nerve stimulation relieves severe depression | WashU Medicine

Results of major clinical trial may pave the way to health insurance coverage for treatment-resistant cases

Washington U. Med December 18, 2024

Tissue factor promotes TREX1 protein stability to evade cGAS-STING innate immune response in pancreatic ductal adenocarcinoma

Oncogene – Tissue factor promotes TREX1 protein stability to evade cGAS-STING innate immune response in pancreatic ductal adenocarcinoma

Oncogene Journal December 18, 2024

Role of GLP-1 agonists in breast cancer survivorship setting

Neil Iyengar, MD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on the potential use of GLP-1 or GLP agonist and incretin mimetics during…

VJ Oncology December 18, 2024

The WHO’s 5th classification for AML: expanding the number of genetically defined categories

Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides insight into the 5th iteration of the World Health Organization’s (WHO)…

VJHemOnc December 18, 2024

Biomarkers and Treatment Strategies in CAR T-Cell Therapy for R/R Multiple Myeloma

Doris K. Hansen, MD, discussed a comprehensive analysis of pretreatment biomarkers associated with outcomes in patients receiving idecabtagene vicleucel therapy

Targeted Oncology December 18, 2024

The current understanding of chimeric antigen receptor (CAR) T-cell therapy for older patients with relapsed or refractory large B-cell lymphoma

Chimeric antigen receptor (CAR) T-cell therapy has changed treatment landscape of relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and more older patients have…

Chimeric Antigen Receptor T-Cell (CAR-T) December 18, 2024

Combined CAR-T/HSCT approach in a patient with refractory acute lymphoblastic leukemia and cystic fibrosis – Benedetta E Di Majo, Francesca Vendemini, Sonia Bonanomi, Pietro Casartelli, Sara Napolitano, Giorgio Ottaviano, Giulia Prunotto, Marta Verna, Alessandra Sala, Guglielmo M Migliorino, Frances

Introduction: The association of acute lymphoblastic leukaemia (ALL) and cystic fibrosis (CF) is rare. We present the case of a paediatric patient affected by C…

Chimeric Antigen Receptor T-Cell (CAR-T) December 18, 2024

Related Articles